中達集團控股(00139.HK)擬成立控股合資企業
格隆匯12月29日丨中達集團控股(00139.HK)發佈公吿,2022年12月28日附屬公司與中啟傳媒科技訂立合作框架協議,據此,於深圳市將成立控股合資企業。控股合資企業將主要從事控股合資企業擬參與的交易。控股合資企業將由附屬公司實益擁有60%,並由中啟傳媒科技擁有餘下40%。
根據合作框架協議的條款,控股合資企業的建議註冊資本將為人民幣1000萬元。附屬公司將以現金出資人民幣600萬元,而中啟傳媒科技將以現金出資人民幣400萬元並由附屬公司承擔,並由附屬公司按照本協議約定向控股合資企業進行注資。附屬公司注資後,即視為中啟傳媒科技完成了註冊資本的實繳義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.